Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD)

NCT04184882 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT04184882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04184882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled Phase 1b Study With Open-Label Extension to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Patients With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Terminated
Start date
February 24, 2021
Completion date
September 4, 2022
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy (dmd)